Online Exclusives

Online Exclusives

Identifying Causes of Cardiomyopathy in Patients With Sickle Cell Anemia

Author’s Perspective Lead author Omar Niss, MD: “Diffuse myocardial fibrosis is a common finding and a newly recognized mechanism of heart disease in sickle cell...

FDA Calls for Manufacturer to Pull Opioid from the Market

The U.S. Food and Drug Administration (FDA) has called for Endo Pharmaceuticals to remove its reformulation of oxymorphone hydrochloride extended-release, Opana ER, because of...

Legislators Propose Two Bills to Lower Drug Prices

Both Democrats and Republicans have introduced bills aimed to lower prescription drug prices: One would renew the U.S. Food and Drug Administration’s (FDA) authority...

NIH No Longer Considering Capping Grants for Individual Labs

In May, the National Institutes of Health (NIH) proposed restricting the amount of funding that an individual laboratory could hold in order to free...

FDA Grants Fast-Track Designation to OXi4503 for AML

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to OXi4503, a vascular disrupting agent shown to cause tumor cell death and...

Cost of Cancer Drugs Expected to Rise by Between 6 and 9 Percent

The price of cancer medications is expected to increase by between 6 and 9 percent each year through 2021, pushing global spending on these...

NIH and Pharmaceutical Companies Join Efforts to Combat Opioid Problems

Federal health agencies and pharmaceutical companies plan to launch a joint effort to combat the current opioid addiction epidemic in the United States. National Institutes...

FDA Approves BLA for Nonacog Beta Pegol for Hemophilia B

The U.S. Food and Drug Administration (FDA) has approved the biologics license application for a modified recombinant coagulation factor IX (FIX) nonacog beta pegol,...

FDA Advisory Committee Supports L-Glutamine for SCD

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 10-3 to support the approval of L-glutamine powder for the treatment of...

FDA’s ODAC Recommends Approval of Epoetin Biosimilars

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of an epoetin alfa biosimilar in a 14-1 vote. This...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.